gemifloxacin gemifloxacin gemifloxacin mesylate (trade name factive, oscient pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. vansen pharma inc. has licensed the active ingredient from lg life sciences of korea. gemifloxacinclinical dataahfs/drugs.commonographmedlineplusa604014pregnancycategory c routes ofadministrationoral/iv under developmentatc codej01ma15 (who) legal statuslegal status in general: ℞ (prescription only) pharmacokinetic databioavailability71%protein binding60–70%metabolismlimited metabolism by the liver to minor metabolitesexcretionfeces (61%); urine (36%)identifiers iupac name 7--1-cyclopropyl-6-fluoro-4-oxo- 1,8-naphthyridine-3-carboxylic acid cas number175463-14-6 ypubchem cid9571107drugbankdb01155 ychemspider7845573 yuniiokr68y0e4tkeggd08012 nchebichebi:101853 ychemblchembl430 ycomptox dashboard (epa)dtxsid3048495 chemical and physical dataformulac18h20fn5o4molar mass389.387 g·mol−13d model (jsmol)interactive image smiles fc2c(nc1n(/c=c(/c(=o)o)c(=o)c1c2)c3cc3)n4c/c(=n\oc)c(c4)cn inchi inchi=1s/c18h20fn5o4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10h,2-3,5-6,8,20h2,1h3,(h,26,27)/b22-14+ ykey:zrcvyeyhrgvloc-hyargmpzsa-n y ny (what is this?) (verify) indications gemifloxacin is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. acute bacterial exacerbation of chronic bronchitis caused by s. pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis community-acquired pneumonia (of mild to moderate severity) caused by s. pneumoniae (including multi-drug resistant strains, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae microbiology gemifloxacin has been shown to be active against most strains of the following microorganisms: aerobic gram-positive microorganisms – streptococcus pneumoniae including multi-drug resistant streptococcus pneumoniae (mdrsp). mdrsp includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. staphylococcus aureus and streptococcus pyogenes aerobic gram-negative microorganisms – haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae (many strains are moderately susceptible), moraxella catarrhalis, acinetobacter lwoffii, klebsiella oxytoca, legionella pneumophila, proteus vulgaris. other microorganisms – chlamydia pneumoniae, mycoplasma pneumoniae adverse effects